文献速递药物不良反应与药物警戒治疗药物监测与药物基因组学

酪氨酸激酶抑制剂吸收不良风险的人工智能建模与生物利用度提升策略

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies.
PubMed 文献 · Br J Clin Pharmacol · 2025-07-08

模型预测酸碱溶解度差异与临床生物利用度相关(P < .001),尼洛替尼、拉帕替尼和达克替尼被列为胃内pH升高时吸收不良风险最高的TKIs。

要点

  • AI模型可识别胃旁路或联用抑酸药时吸收不良风险高的TKIs。
  • 尼洛替尼、拉帕替尼和达克替尼被列为最高风险药物。
  • 高风险药物可通过个案化吸收增强方法改善生物利用度。

核心结论

  • AI模型可预测TKIs在绕过胃或联用胃酸抑制药时的吸收不良风险,高风险药物可通过多种方法增强生物利用度。

主要发现

  • 预测酸碱pH间溶解度差异的AI模型 Pearson相关系数为 .95、决定系数为 .90。
  • 酸碱pH间溶解度差异与临床生物利用度相关(P < .001)。
  • 尼洛替尼、拉帕替尼和达克替尼被列为胃内pH升高时吸收不良风险最高的TKIs。

临床怎么用

  • 对接受减重手术或联用质子泵抑制剂的TKIs患者,可用AI模型评估吸收不良风险并考虑吸收增强策略,并以治疗药物监测评估增强效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton-pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are susceptible to reduced absorption in these patients, and the application of case-specific absorption enhancements based on 2 clinical scenarios. METHODS: A fully connected neural network was applied using pH-dependent solubility data from 137 785 compounds to identify TKIs at risk of reduced bioavailability when bypassing the stomach. The clinical impact of gastric acid suppressants on the bioavailability of 71 approved TKIs was evaluated by correlating the AI solubility estimates with the effect of proton-pump inhibitors on clinical exposure. Furthermore, absorption enhancement was applied in 2 clinical scenarios, with therapeutic drug monitoring assessing the effectiveness of the enhancement. RESULTS: Two AI models were developed to predict the difference in molecular aqueous solubility between acid and neutral pH and to capture the concentration available for intestinal absorption in healthy and in patients with malabsorption issues. The AI model capturing the solubility difference between acidic and neutral pH demonstrated predictive capabilities, with a Pearson correlation coefficient of .95 and a coefficient of determination of .90. It predicted that the solubility difference, between acidic and neutral pH, was associated with clinical bioavailability (P < .001). Nilotinib, lapatinib and dacomitinib were ranked as TKIs with the highest risk of malabsorption in case of increased stomach pH. CONCLUSION: We developed an AI-based model that predicts TKIs that are at risk of malabsorption when bypassing the stomach or used with gastric acid suppressants. Drugs with a high malabsorption risk can be enhanced by various methods to improve bioavailability.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Huntjens DW, Béquignon OJM, Krens SD, et al. Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies. Br J Clin Pharmacol. 2025. PMID: 40625205. doi:10.1002/bcp.70166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。